# US 2001/0026928 A1 · Anti-C2/C2a inhibitors of complement activation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026928 A1
- Document ID: US20010026928A1
- Status: Published application
- Kind: A1
- Application number: 09/816,839
- Filed: 2001-03-23
- Published: 2001-10-04
- Earliest claimed: 2000-03-23
- Assignees: Tanox, Inc.
- Inventors: Michael S.C. Fung; Cecily R.Y. Sun; William N.C. Sun
- Web page: https://patentgrep.com/patent/US20010026928A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/18: against material from animals or humans
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.

## Claims

### Claim 1

An inhibitor molecule that binds to C2a or the C2a portion of C2.

### Claim 2

An inhibitor molecule that binds to C2a or the C2a portion of C2 and inhibits both the classical and the lectin complement pathways.

### Claim 3

An inhibitor molecule that binds to the same epitope as the monoclonal antibody 175-62.

### Claim 4 (depends on 1, 2)

The inhibitor molecule of any one of claims 1, 2, or 3, wherein said molecule is an antibody or a homologue, analogue or fragment thereof, a peptide, an oligonucleotide, a peptidomimetic or an organic compound.

### Claim 5 (depends on 4)

The inhibitor molecule of claim 4, wherein the antibody fragments are Fab, F(ab′)2, Fv or single chain Fv.

### Claim 6 (depends on 5)

The inhibitor molecule of claim 5, wherein the antibody is monoclonal.

### Claim 7 (depends on 6)

The monoclonal antibody of claim 6, wherein the antibody is a chimeric, Delmmunized™, humanized or human antibody.

### Claim 8

A monoclonal antibody 175-62.

### Claim 9

A cell line that produces the monoclonal antibody 175-62.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the inhibitor molecule of claim 1 and a pharmacologically acceptable carrier, excipient, stabilizer, or diluent.

### Claim 11

A method of inhibition of complement activation comprising administering an inhibitor molecule that binds C2a or the C2a portion of C2.

### Claim 12

A method of inhibition of the classical and lectin complement pathways comprising administering an inhibitor molecule that binds C2a or the C2a portion of C2.

### Claim 13 (depends on 11)

The method of claim 11, wherein the inhibition of complement activation is determined in vitro.

### Claim 14 (depends on 11)

The method of claim 11, wherein the molar ratio of inhibitor molecule to C2 is less than or equal to 1:2.

### Claim 15 (depends on 1, 2, 3, 8, 10)

A method of treating a disease or condition that is mediated by excessive or uncontrolled activation of the complement system comprising administering, in vivo or ex vivo, an inhibitor molecule according to any of claims 1 to 3, 8 or 10.

### Claim 16 (depends on 15)

The method of claim 15, wherein the inhibitor molecule is administered by intravenous infusion, intravenous bolus injection, intraperitoneal, intradermal, intramuscular, subcutaneous, intranasal, intratracheal, intraspinal, intracranial, or orally.

### Claim 17 (depends on 4)

A diagnostic method comprising the detection of the amount of C2 or C2a present in a sample with the inhibitor molecule of claim 4.

### Claim 18 (depends on 17)

The diagnostic method of claim 17, wherein the inhibitor molecule is the monoclonal antibody 175-62.
